Trial Profile
A Single Centre, Open label, Single Arm, Phase I Study to evaluate the Tolerability, Safety and Immunogenicity of a 15-Valent Pneumococcal Conjugate Vaccine (PCV15) in healthy subjects between 18-45 years of age - 15-Valent Pneumococcal Conjugate Vaccine (PCV15)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jul 2019
Price :
$35
*
At a glance
- Drugs V 114 (Primary)
- Indications Pneumonia
- Focus Adverse reactions
- Sponsors Aurobindo Pharma; Tergene Biotech
- 22 Jun 2018 New trial record